Premium
Enfuvirtide: a new class of antiretroviral therapy for HIV infection
Author(s) -
Leao JC,
Frezzini C,
Porter S
Publication year - 2004
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/j.1601-0825.2004.01042.x
Subject(s) - enfuvirtide , antiretroviral therapy , medicine , human immunodeficiency virus (hiv) , virology , immunology , viral load , antigen , gp41 , epitope
Enfuvirtide is the first of a new class of antiretroviral agents recently approved for the treatment of human immunodeficiency virus (HIV)‐1 infection. Present available data suggest that enfuvirtide may be a promising agent for the control of HIV infection in patients who have previously received reverse transcriptase inhibitor and protease inhibitor regimens and who are either intolerant to such drugs and/or who have gone into virological failure. Perhaps the greater limitation to the clinical use of enfuvirtide is the cost, limiting its use in the developing world.